RECENT NEWS

Danaher has launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild traumatic brain injury (TBI). As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Danaher subsidiary Beckman Coulter Diagnostics to potentially establish correlations between a new biomarker panel and clinical outcomes.

Harnessing the power of CRISPR gene-editing technology in a new way, University of Florida researchers have created a one-tube testing method targeting DNA from body fluids that has the potential to dramatically increase access to the diagnosis of viral diseases such as cervical cancer.

A newly discovered Zika virus-specific synthetic molecule is capable of differentiating Zika-immune patient samples from samples of patients previously infected with the related dengue virus. The technology may lead to the development of better diagnostics and vaccine candidates.

Applied Cells has announced the launch of its MARS Ingenuity Reagent kits for fast and easy cell isolation. This innovative product line features both RUO and GMP-grade reagents, and has been specifically optimised for use on Applied Cells’ proprietary MARS Bar platform.

Registration is now open for the Infection Diagnostics Symposium, hosted by BD, which aims to bring together professionals from the laboratory, ward and board across two days to discuss how a unified approach could improve infectious disease diagnostic pathways.

Construction work is underway for two new NHS community diagnostic centres (CDCs) in Lincolnshire as part of a £38million investment in services. The centres in Skegness and Lincoln represent a significant development in local NHS services, with the centre in Skegness believed to be the largest single NHS investment in the town in many years.

Beckman Coulter Diagnostics and MeMed, a leader in the emerging field of advanced host-response technologies, have announced the expansion of their host immune response diagnostics partnership.

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched AI Airlock, its new regulatory sandbox for AI as a Medical Device (AIaMD). This initiative aims to address challenges for regulating medical devices that use AI.

The Association of British HealthTech Industries (ABHI) has published its manifesto which articulates a clear and actionable 10-point programme for government. This strategic blueprint is designed to harness the full potential of the sector to benefit patients, clinicians, and the UK economy.

The government has announced its new national action plan on antimicrobial resistance to protect people and animals from the risk of drug-resistant infections. The new document builds on the progress made in the previous five-year national action plan and supports the 20-year vision to contain and control AMR by 2040.

Working towards a multidisciplinary approach to navigate the future of infectious diseases was a key theme at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2024 congress.

Researchers have developed a vaccine that has been shown in mice to protect against a broad range of coronaviruses with potential for future disease outbreaks. This is a new approach to vaccine development called ‘proactive vaccinology’, where scientists build a vaccine before the disease-causing pathogen even emerges.

BBI Solutions a trusted expert provider of end-to-end solutions for the development of high-performance assays, has signed a partnership agreement with BioAgilytix, a leading global bioanalytical laboratory. The partnership will integrate BBI’s ability to produce high-quality custom antibody reagents for a variety of testing applications with BioAgilytix’s bioanalytical testing services.

Broken String Biosciences, a genomics company driving development of cell and gene therapies, has announced it has entered a research collaboration with the Francis Crick Institute, to further understand the development of amyotrophic lateral sclerosis (ALS).

QuidelOrtho has announced that its Board of Directors has appointed Brian J Blaser as President and CEO. In addition, Mr. Blaser will also join the Board later this month as it expands from ten to eleven members.

Geneoscopy, a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, has announced that the US Food and Drug Administration (FDA) approved its non-invasive colorectal cancer (CRC) screening test, ColoSense.

Researchers at ETH Zurich have developed a new device for taking blood samples. It works according to the leech principle and is less invasive than taking blood from the arm with a needle. It is also easy to handle and can be used by people without medical training.

A new £42m trial called TRANSFORM is aiming to find the best way to screen men for prostate cancer and is co-funded by Prostate Cancer UK and the National Institute for Health and Care Research (NIHR). Thousands more men could be saved every year as the new trial aims to double the efficacy of prostate cancer screening.

Quest Diagnostics, and PathAI have announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases. Under the terms of a definitive agreement, Quest will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services.

The Institute for Biomedical Science (IBMS) has revealed the shortlists in 12 categories for its inaugural awards. Over 100 entrants have been narrowed down to just over 50 exceptional nominees, showcasing the immense talent within the biomedical science community.